Drug Trial Radar · NCT07938242
Comparison of Local Methylcobalamin and Subcutaneous Lidocaine in Subacute Herpetic Neuralgia
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Mar 1, 2027
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- CMH Multan Institute of Medical SciencesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized controlled trial will compare methylcobalamin and lidocaine injections for pain relief in 60 patients with subacute herpetic neuralgia over four weeks.
Conditions
- Subacute Herpetic Neuralgia
Interventions
MethylcobalaminDrug
Methylcobalamin injection (1 mg/2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.
Injection lidocaineDrug
Lidocaine inLidocaine injection (1%, 2 mL) administered subcutaneously into up to four painful areas, with 0.5 mL injected at each area according to the patient's reported painful areas, six times per week for four weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain scoreTime frame: Baseline (Day 1) and Day 28 (end of treatment).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cmh Multan
Multan, Punjab Province, Pakistan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.